Boston Scientific (NYSE:BSX) won CE Mark approval in the European Union for expanded use of its Watchman heart device, the medical device giant announced over the weekend.
Atritech Inc.
Stents: “Remarkable” results for MDT’s Resolute in patients with both diabetes and heart diseases | PCR 2011 Roundup
Medtronic Inc. (NYSE:MDT) said that its Resolute drug-eluting stent could level the playing field for cardiac patients suffering from diabetes in a study of nearly 1,000 patients.
The results of the pooled clinical trial are important because diabetic patients with heart disease generally have an increased risk of heart attack or other major cardiovascular event, and they’re targets for repeat procedures, according to Sigmund Silber of the Heart Catheterization Centre in Munich, Germany.
Boston Scientific closes Atritech takeover | Acquisitions roundup
Boston Scientific Corp. (NYSE:BSX) completed its buyout of Plymouth, Minn.-based Atritech Inc.
Atritech’s CE Mark-approved Watchman device is designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.
The $100 million cash deal, which was announced in January, could reach a value of $375 million with the addition of future milestone payments.
Boston Scientific to pick up Atritech for up to $375 million
Boston Scientific Corp. (NSYE:BSX) agreed to acquire Plymouth, Minn.-based Atritech Inc. for $100 million in cash plus milestone payments of up to $275 million more through 2015.
Atritech’s CE Mark-approved Watchman device is designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.